A prospective, post-authorization, international study of UPadacitinib to evaluate its rapid onset and durability of effectiveness in real-world clinical practice in patients with moderate to severe Crohn's disease over 3 years (UPlift)

OBSERVATIONAL STUDY WITH MEDICINES